NCI issued an announcement encouraging treatment with anticancer drugs via two methods, after surgery, for women with advanced ovarian cancer. The combined methods, which deliver drugs into a vein and directly into the abdomen, extend overall survival for women with advanced ovarian cancer by about a year.

The clinical announcement was made with the support of six professional societies and advocacy groups. The announcement coincides with publication in the New England Journal of Medicine of the results of a large clinical trial by Deborah Armstrong, M.D., medical oncologist and an associate professor at Johns Hopkins Kimmel Cancer Center in Baltimore, Md., and her colleagues in an NCI-supported research network known as the Gynecologic Oncology Group (GOG). This is the eighth trial evaluating the use of chemotherapy delivered into the abdomen for ovarian cancer. Together, these trials show a significant improvement in survival for women with advanced ovarian cancer.

The two treatment methods are called intravenous, or IV, for chemotherapy delivered into a vein and intraperitoneal, or IP, for chemotherapy delivered into the abdominal, or peritoneal, cavity.

Clinical Annoucement, Press Release and Q & A , IP Chemotherapy Digest Page

Digital Mammography Trial Results Announced
September 16, 2005

Women with Dense Breasts, Women Younger than 50, and Those Who Are Perimenopausal May Benefit from Digital Mammograms DMIST Press Release DMIST Questions and Answers

CTWG Report

Recommendations Accepted to Revamp NCI Clinical Trials System
June 7, 2005
The National Cancer Advisory Board (NCAB) of the National Cancer Institute (NCI) today accepted 22 strategic proposals for revamping the NCI’s cancer clinical trials system and a five-year implementation plan to accomplish the changes. more >